**Title**

The association of circulating fibroblast growth factor 21 levels with incident heart failure: The Multi-Ethnic Study of Atherosclerosis.

**Permalink**

https://escholarship.org/uc/item/7307k5x0

**Authors**

Tucker, William

McClelland, Robyn

Allison, Matthew

et al.

**Publication Date**

2023-06-01

**DOI**

10.1016/j.metabol.2023.155535

Peer reviewed

# The association of circulating fibroblast growth factor 21 levels with incident heart failure: The Multi-Ethnic Study of Atherosclerosis

William Tucker[a], Robyn L. McClelland[b], Matthew A. Allison[c], Moyses Szklo[d], Kerry-Anne Rye[a], Kwok Leung Ong[a,e,*]

[a]School of Biomedical Sciences, University of New South Wales, Sydney, NSW, Australia

[b]Department of Biostatistics, University of Washington, Seattle, WA, United States

[c]Department of Family Medicine, University of California San Diego, La Jolla, CA, United States

[d]Department of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

[e]NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia

## Abstract

**Background:** Fibroblast growth factor 21 (FGF21) levels are often elevated in heart failure (HF), although this has not been assessed using a longitudinal study design. Therefore, we investigated the association between baseline plasma FGF21 levels and incident HF in the Multi-Ethnic Study of Atherosclerosis (MESA).

**Methods:** A total of 5408 participants, free of clinically apparent cardiovascular disease, were included in the analysis, of which 342 developed HF over a median follow-up period of 16.7 years. Multivariable Cox regression analysis was performed and the additive value of FGF21 in the performance of risk prediction over other well-established cardiovascular biomarkers was assessed.

**Results:** The mean age of the participants was 62.6 years with 47.6 % male. Regression spline analysis demonstrated a significant association of FGF21 levels with incident HF among participants with FGF21 levels   239.0 pg/mL (hazard ratio = 1.84 [95 % confidence interval 1.21, 2.80] per SD increase in ln-transformed levels) after adjustment for traditional cardiovascular

*Corresponding author at: Room 134, Medical Foundation Building, 92-94 Parramatta Road, Camperdown, NSW 2050, Australia. oklws@yahoo.com.hk (K.L. Ong).

risk factors and biomarkers, but not in participants with FGF21 levels <239.0 pg/mL (p for heterogeneity = 0.004). Among participants with FGF21 levels 239.0 pg/mL, FGF21 levels were associated with HF with preserved ejection fraction (HR [95 % CI] = 2.57 [1.51, 4.37]), but not HF with reduced ejection fraction.

**Conclusions:** The present study suggests baseline FGF21 levels could predict the development of incident HF with preserved ejection fraction, among participants with elevated FGF21 levels at baseline. This study may suggest a pathophysiological role of FGF21 resistance in HF with preserved ejection fraction.

### Keywords

Fibroblast growth factor 21; Heart failure; Heart failure with preserved ejection fraction; Biomarker; Multi-Ethnic Study of Atherosclerosis

## 1. Introduction

Heart failure (HF) is a chronic, progressive clinical syndrome characterised by an inability to generate a cardiac output sufficient to meet physiologic demands [1]. Clinically, HF is a major global health problem with a 5-year mortality rate of 45 % [2] and a prevalence that is predicted to rise with ageing. The progressive nature of the condition results in a significant economic burden, with the average annual healthcare costs for a patient with HF amounting to approximately $27,000 in the Western world [3]. As such, it is paramount that individuals at increased risk or in the early stages of HF be identified to facilitate early intervention.

Recent studies have suggested fibroblast growth factor 21 (FGF21) as a promising biomarker candidate for HF. FGF21 is a peptide hormone that is involved in energy homeostasis. It protects against various pathophysiologic processes intrinsically related to HF development, namely cardiac oxidative stress [4], hypertrophy [5] and inflammation [5] as demonstrated in animals and in vitro cell culture studies. In clinical studies, however, FGF21 levels are often elevated in cardiovascular diseases, including HF [6,7]. The paradoxical increase reported in these conditions has been suggested to be due to FGF21 resistance [8,9].

Previous studies have assessed the relationship between FGF21 levels and prevalent HF using cross-sectional study designs. The majority of such studies confirm an association between elevated FGF21 levels and HF, however, conclusions are limited by small sample sizes, a lack of information on cohort ethnicity and differing baseline characteristics [10]. As such, this study aimed to investigate the prospective association between baseline FGF21 levels and incident HF in the Multi-Ethnic Study of Atherosclerosis (MESA), a large, ethnically diverse cohort of participants free of clinically apparent cardiovascular disease (CVD) at baseline [11]. In this study, we additionally assessed the association of FGF21 levels with HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).

## 2.   Materials and methods

### 2.1.   Study participants

MESA is a prospective cohort study of participants free of clinically apparent CVD at baseline, designed to assess risk factors, prevalence, and progression of subclinical CVD. Details regarding the MESA study design have been described previously [11]. Briefly, the cohort is comprised of 6814 men and women, aged 45–84 years from four major racial/ethnic groups, namely non-Hispanic Whites, African Americans, Hispanic Americans, and Chinese Americans. Participants were recruited in 2000–2002 from six field centers across the United States (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; New York, NY, and St. Paul, MN) and were followed up for CVD events, including HF, up to 31 December 2018. Sampling was performed to provide balanced recruitment across strata defined by gender, ethnicity, and age group (45–54, 55–64, 65–74, and 75–84 years). The study was approved by institutional review boards at all participating centres. Informed written consent was obtained from participants upon arrival at the relevant field center. A random subgroup of approximately 1000 participants had limited availability of plasma samples for FGF21 measurement, leaving 5792 participants in the final population with valid data on plasma FGF21 levels. After further excluding 23 participants with missing data on incident HF, 4 participants with pre-existing peripheral vascular disease at baseline and 357 with self-reported liver/kidney disease at baseline, a total of 5408 participants were included in this analysis (Supplementary Fig. 1). To avoid potential confounding, participants with baseline liver and kidney diseases were excluded from the analysis. This is because FGF21 is primarily secreted by the liver, and both liver and renal functions are closely related to cardiac function, with the circulating FGF21 levels often elevated in participants with both these conditions [12,13].

### 2.2.   FGF21 measurement

At baseline exam, using standard venepuncture technique, peripheral venous blood samples were collected from participants following a 12-h fast. FGF21 levels were measured in plasma samples using enzyme-linked immunosorbent assay kits (Antibody and Immunoassay Services, University of Hong Kong, Hong Kong) as previously described [14]. These samples were stored at −70 °C for >14–16 years before FGF21 measurement. Intra-assay and inter-assay coefficients of variation were both <10 %. Technicians that performed the analyses were blinded to participant information and identity.

### 2.3.   Other covariates of interest

A standardized questionnaire was used to ascertain information on participant demographics, socioeconomic status, medical and family history, medication use, smoking status, smoking pack-years, alcohol consumption, and physical activity. Resting blood pressure (BP) was assessed at the baseline exam utilizing a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, Florida) along with height and weight for calculation of body mass index (BMI). Seated blood pressure was measured three times with the final two readings averaged for use in the analysis. Coronary artery calcium (CAC) was measured with either electron-beam computed tomography or multidetector computed tomography. The extent of calcification was quantified using the

Agatston scoring method [15]. Cardiac magnetic resonance imaging (MRI) was used for measurement of left ventricular (LV) mass, LV end diastolic and systolic volume and LV ejection fraction [16]. Of the 6814 participants, 5098 participants underwent cardiac MRI of which 5004 had valid data [17].

Total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were assayed as described previously [18]. The Friedewald equation was utilized to estimate low-density lipoprotein (LDL) cholesterol in plasma samples with a triglyceride value <400 mg/dL. LDL cholesterol in samples with a triglyceride value >400 mg/dL were not measured. Serum fasting glucose was determined by reflectance spectrophotometry with the Vitros analyser (Johnson & Johnson Clinical Diagnostics, Rochester, NY). The estimated glomerular filtration rate (eGFR) was calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration Eq. [19]. The homeostasis model assessment of insulin resistance index (HOMA2-IR) was calculated as described previously [20]. Interleukin-6 (IL-6), C-reactive protein (CRP), fibrinogen, N-terminal pro-brain natriuretic peptide (NT-proBNP), and γ-glutamyl transferase (GGT) levels were measured as previously described [21–23].

### 2.4. HF and coronary heart disease determination

Participants were contacted at 9–12-month intervals to identify CVD events, including HF and coronary heart disease (CHD). Self-reported cardiovascular events were confirmed by requesting hospital or outpatient medical record documentation. Trained personnel abstracted medical records indicating any possible CVD events which were then reviewed independently by two physicians for event classification [18]. Disagreements between physicians were adjudicated by a third reviewer for final endpoint classification. HF diagnosis was defined as probable or definite HF. Probable HF included participants who had been diagnosed as having HF by a physician and were receiving treatment. HF was classified as definite if one or more of the following criteria were also present: evidence of pulmonary edema/congestion on chest X-ray, dilated ventricle, poor left ventricular (LV) function on echocardiography or ventriculography, or evidence of left ventricular diastolic dysfunction. Definite and probable HF were combined as the endpoint in this study. In patients with a recorded ejection fraction, the first HF event was classified as HFrEF or HFpEF, which were defined as ejection fraction <45 % and ≥45 % respectively [24]. CHD was defined as the composite endpoint of myocardial infarction, resuscitated cardiac arrest, definite angina, probable angina, and CHD death.

### 2.5. Statistical analysis

Statistical analysis was conducted using SPSS 28 (IBM, Armonk, NY), STATA 17 (StataCorp, College Station, TX) and R 4.2.1 (The R Core Team, Vienna, Austria). Comparison of baseline clinical characteristics between participants with and without incident HF was performed by chi-square test for categorical variables and independent $t$-test for continuous variables. Adjustment for age, sex, and race/ethnicity was performed using Cox regression analysis. Variables with highly skewed distributions were transformed using natural logarithms (ln) prior to analysis. Participants with missing data for a variable

were excluded from the analysis of that variable. Unless otherwise stated, a *p* value <0.05 was considered statistically significant.

The correlates of ln-transformed plasma FGF21 levels were assessed by multivariable linear regression analysis. Regression coefficients (B) were expressed as the percentage change in FGF21 levels per one standard deviation (SD) increment in continuous variables. Data were presented as unadjusted and then subsequently adjusted for age, sex, and race/ethnicity in model 1. In order to decrease the beta error, variables with $p < 0.2$ in model 1 were then used as covariates for adjustment in model 2. In the full adjustment model, no multicollinearity was identified based on variance inflation factors (<3.0 for all variables).

Cumulative survivals across FGF21 quartiles were estimated by the Kaplan-Meier method and compared by the log-rank test. The association of baseline FGF21 levels with incident HF and its two sub-types (HFpEF and HFrEF) was assessed by Cox regression analysis. The proportional hazard assumption was checked by using Schoenfeld residuals. Hazards ratio (HR) and 95 % confidence interval (CI) were expressed per one SD increase in ln-transformed FGF21 levels. In model 1, data was adjusted for demographic and socioeconomic variables, including age, sex, race/ethnicity, education, and family income. Model 2 was further adjusted for traditional cardiovascular risk factors, including body mass index (BMI), physical activity, smoking, smoking pack-years, alcohol consumption, LDL cholesterol, HDL cholesterol, triglycerides, lipid-lowering medications, eGFR, systolic blood pressure (SBP), anti-hypertensive medications, diabetes, and HOMA2-IR. In model 3, the data were further adjusted for well-established CVD risk biomarkers, including CRP, IL-6, fibrinogen, and NT-proBNP. NT-proBNP and FGF21 levels were highly skewed and were ln-transformed in the Cox regression analysis to prevent unstable estimates given extreme values may impact estimation of the regression coefficient. CRP and IL-6 were also skewed however to a lesser extent and therefore not ln-transformed in the analysis. In a separate analysis, similar results were obtained when using ln-transformed CRP and IL-6. The relationship of FGF21 levels with incident HF were assessed for potential nonlinearity using restricted cubic regression splines by the "mvrs" program in STATA. The relationship was allowed to be nonlinear with a maximum of 4 knots and knot positions being determined according to equally spaced percentiles of the continuous FGF21 distribution. We assumed a linear relationship of all other covariates with incident HF. When nonlinearity was detected, the approximate knot positions were used to fit regression analyses within strata defined by these thresholds.

All analyses were assessed for potential interactions by sex and race/ethnicity. The p for heterogeneity was estimated by including the multiplicative interaction term in the regression models in the full sample after adjusting for the main effects of the covariates. In a separate analysis, a time-dependent Cox regression model was used to account for the possibility that interim incident CHD might have been a confounder. A sensitivity analysis was performed with further adjustment for GGT levels and CAC score to assess the potential confounding effect of liver function and subclinical atherosclerosis, respectively. In a separate analysis, data was further adjusted for health insurance status to minimize the confounding effect of access to health care. In a separate sensitivity analysis, the analysis was repeated after removing the first 3 and 5 years of follow-up separately to reduce

potential reverse causality. Furthermore, given FGF21 levels can be affected by heavy drinking and are related to alcohol appetite [25], a subgroup analysis was performed with participants categorised by the number of alcoholic drinks per week. Finally, the incremental value of the addition of ln-transformed FGF21 levels in risk prediction model for HF was assessed by the change in Harrell's C-statistic using the likelihood ratio test and the category-free net reclassification improvement (NRI > 0) as previously described [26,27]. The May and Hosmer test was used to assess the goodness-of-fit of the risk prediction models [28].

## 3.   Results

### 3.1.   Baseline characteristics

A total of 5408 participants were included in the analysis, of which 342 developed HF over a median follow-up period of 16.7 years. Compared to 1406 excluded participants, those included in the study were older and a higher proportion were African American (Supplementary Table 1).

The baseline characteristics of the included participants are shown in Table 1. Participants with incident HF were older, and more likely to be male, have diabetes and take anti-hypertensive medications at baseline. Such participants had higher BMI, number of pack-years of smoking, triglycerides, BP, HOMA2-IR, IL-6, CRP, NT-proBNP, FGF21 and fibrinogen levels, and lower HDL cholesterol and eGFR. Among participants with incident HF, there was a larger proportion of African Americans and Non-Hispanic Whites. Those that developed HF also had a lower education attainment level and family income. There were also significant differences in cardiac MRI parameters, with higher LV end diastolic mass, LV end diastolic volume, LV end systolic volume and LV stroke volume, and a lower LV ejection fraction among incident HF patients.

As shown in Supplementary Table 2, participants who developed HFpEF were older, more likely to be female and Chinese American, and less likely to be African American as compared to those who developed HFrEF.

The association between each covariate and FGF21 levels are illustrated in Table 2. In the final multivariable model, FGF21 levels were higher with higher age, triglycerides, systolic BP, HOMA2-IR, IL-6 and CRP levels. The levels were also higher in current smokers and participants with diabetes. FGF21 levels were lower in former drinkers, as well as in Chinese and African American ethnicities. In addition, the levels were lower with higher physical activity, eGFR and fibrinogen levels.

### 3.2.   FGF21 and incident HF

As shown in Fig. 1, HF incidence increased from the lowest to the highest FGF21 quartile. Table 3 shows the association of baseline FGF21 levels with incident HF. In model 1, higher baseline FGF21 levels were associated with HF development. However, the association became non-significant after adjustment for traditional CVD risk factors in model 2. Similar non-significant results were obtained when assessing FGF21 quartile levels (Supplementary Table 3). However, when assessing the non-linear relationship of FGF21 levels with

incident HF, an approximate knot position of 5.48 in ln-transformed FGF21 levels, which corresponded to an FGF21 level of 239.0 pg/mL (i.e. 74th percentile), was found (Fig. 2). In participants with an FGF21 level 239.0 pg/mL, a significant association of ln-transformed FGF21 levels with incident HF was observed (HR [95 % CI] = 1.84 [1.21, 2.80]) even after adjustment for traditional CVD risk factors and CVD risk biomarkers, but not in those with FGF21 level < 239.0 pg/mL (p for heterogeneity = 0.004). No significant heterogeneity with sex and race/ethnicity was found. Supplementary Table 4 shows the baseline characteristics of the participants with FGF21 levels <239.0 and 239.0 pg/mL.

### 3.3. FGF21 levels in HFpEF and HFrEF

As shown in Table 3, there was a significant association between baseline FGF21 levels and HFpEF in model 1 that became non-significant with adjustment for traditional CVD risk factors. However, a significant association was found with HFpEF in the full adjustment models (HR [95 % CI] = 2.57 [1.51, 4.37]) in participants with FGF21 levels 239.0 pg/mL, but not in those with FGF21 level < 239.0 pg/mL (p for heterogeneity <0.001). No association was found between baseline FGF21 levels and HFrEF in any of the analyses. No significant heterogeneity with sex and race/ethnicity was found.

### 3.4. Sensitivity analyses

In sensitivity analyses, the association of baseline FGF21 levels with incident HF and HFpEF among participants with FGF21 levels 239.0 pg/mL remained significant after further adjustment for GGT levels and/or CAC score, or health insurance status, as well as after removing the first 3 and 5 years of follow-up separately (Supplementary Table 5). As shown in Supplementary Table 6, among 3912 participants with data on cardiac MRI parameters, the associations of FGF21 levels with incident HF and HFpEF among participants with FGF21 levels 239.0 pg/mL at baseline remained statistically significant after further adjustment for cardiac MRI parameters. In a separate analysis, the association of baseline FGF21 levels with incident HF and HFpEF among participants with FGF21 levels 239.0 pg/mL remained statistically significant after further adjustment for incident CHD as a time-dependent variable (Supplementary Table 7). Moreover, there were no statistically significant differences between the observed association with HF across alcohol consumption levels (Supplementary Table 8).

### 3.5. Incremental predictive performance of elevated FGF21 levels for HFpEF

As FGF21 levels predicted incident HFpEF, but not HFrEF, we assessed the incremental predictive performance of elevated FGF21 levels for HFpEF among all participants using a piecewise Cox regression model with two slopes and a change point at a FGF21 level of 239.0 pg/mL. As shown in Table 4, among the 5 biomarkers, including FGF21, only NT-proBNP increased the HF risk prediction performance when compared to a base model with only demographic factors and traditional CVD risk factors as assessed by both C-statistics and NRI. Nevertheless, FGF21 could further improve the predictive performance of a model containing NT-proBNP, regardless of the presence or absence of the other three biomarkers. All the examined models exhibited a high goodness of fit.

## 4. Discussion

To our knowledge, the present study was the first to investigate the relationship of circulating FGF21 levels with incident HF with a longitudinal study design. Our study showed a threshold for the relationship of FGF21 levels with incident HF, in which FGF21 levels were significantly associated with incident HF exclusively in participants with elevated baseline FGF21 levels. Stratifying HF into its respective subtypes, we observed that FGF21 levels were related to incident HFpEF, but not HFrEF. No significant heterogeneity was found with sex and racial/ethnic groups in all the analyses. Additionally, FGF21 could improve the risk prediction of HFpEF over a model with traditional CVD risk factors and NT-proBNP.

The finding of raised circulating FGF21 levels in HF in humans is paradoxical to preclinical evidence where FGF21 attenuated cardiac oxidative stress [4], hypertrophy and inflammation [5] in animal and in vitro studies, therefore potentially protecting against the development of HF. This suggests that the elevated circulating FGF21 levels could be due to a compensatory response to comorbid metabolic conditions which precipitated HF. Alternatively, it may be due to the presence of FGF21 resistance which is caused by the impaired expression and downstream signalling pathways of the FGF21 receptor complex, leading to the need for a higher FGF21 level to exert its normal physiological function [8,29,30]. The phenomenon of FGF21 resistance was first discovered in relation to the liver and adipose tissue [8], however, impaired cardiac expression of the FGF21 receptor complex has since been reported in obese rats [31]. This suggests that FGF21 resistance occurs in the heart and in response to obesity, a risk factor for HF.

In this study, an association between baseline FGF21 levels and incident HF was found exclusively among participants with elevated FGF21 levels at baseline. One possible explanation may relate to the presence of FGF21 resistance. We hypothesize that an increase in FGF21 levels beyond the cut-off value of 239.0 pg/mL may represent more severe FGF21 resistance and therefore a greater extent of underlying metabolic/cardiac dysfunction related to HF development such as oxidative stress and inflammation. At a level below this cut-off value, FGF21 and its downstream signalling pathways may function normally with minimal or absent FGF21 resistance, and therefore increases in FGF21 within this range may reflect its normal physiological and metabolic properties. Further studies are needed to validate our hypothesis and assess whether the relationship of FGF21 with other cardiometabolic conditions would be stronger beyond a particular FGF21 level and whether such observations could be replicated in other independent cohorts.

In concordance with previous studies, higher FGF21 levels were associated with an adverse CVD risk profile [32]. However, our study results do not support an association of higher FGF21 levels with higher physical activity as reported previously [33]. Our study additionally reported an association of lower fibrinogen levels with a higher FGF21 level which is also not consistent with results in previous studies [34,35]. However, this association is not appear well-established [14] and may vary depending on patient characteristics.

In the present study of participants with elevated FGF21 at baseline, higher FGF21 levels were associated with incident HFpEF but not HFrEF. This suggests that FGF21 levels may potentially be able to identify people at risk of different HF subtypes. This is important considering the substantial differences between HFpEF and HfrEF. The identification of FGF21 as an effective biomarker would assist in the early detection of high-risk patients, hence improving early treatment decisions and outcomes. Our study suggests that FGF21 is likely better suited to a multi-biomarker panel where it can further improve the performance of a model with traditional risk factors and NT-proBNP for prediction of incident HfpEF. The natriuretic peptides are the gold standard for biomarkers for HF in clinical practice. However, as they are limited by low specificity [36], FGF21 may be of value in improving its diagnostic capabilities. Further studies are needed to investigate the clinical value of FGF21 levels in the prognosis and management of patients with HF.

In previous cross-sectional studies, FGF21 has been shown to be elevated in both HFrEF and HFpEF [10]. The underlying mechanism for FGF21 elevation in HFpEF may relate to the presence of congestive hepatopathy, which may act as a signal for FGF21 production in a hepatic to cardiac signalling loop [37] that feeds back to the heart where it exerts its cardioprotective functions. Given liver pathologies such as non-alcoholic liver disease and complications such as congestive hepatopathy are more prevalent in HFpEF than in HFrEF [38,39], raised FGF21 levels in HFpEF may reflect this compensatory protective feedback loop. As such, it was hypothesised that congestive hepatopathy may be responsible for the elevation in FGF21 in those who developed HFpEF. Although participants with self-reported liver disease were excluded in the present study, the presence of subclinical or undiagnosed congestive hepatopathy may contribute to the relationship between FGF21 and incident HFpEF. GGT is a cell surface enzyme widely used to diagnose hepatobiliary pathologies and is often elevated in patients with congestive hepatopathy [40]. However, further adjustment for GGT did not attenuate the association in a sensitivity analysis. Nevertheless, GGT is not a well-established specific marker for congestive hepatopathy. Furthermore, congestive hepatopathy does not exclusively occur in HFpEF and may also be present in HFrEF if there is right-sided ventricular involvement. Another potential reason for the elevation of FGF21 levels in HFpEF may be due to the recognised central role of metabolic disturbances and inflammatory pathways to the pathophysiology of HFpEF [41]. This is in contrast to HFrEF where the involvement of metabolic dysregulation in the development of HFrEF is less pronounced than that in HFpEF [42]. Given FGF21 levels are related to glucose and lipid metabolism, in the setting of FGF21 resistance, the prevalence of metabolic dysregulation in HFpEF may account for the elevation in FGF21 levels. Nonetheless, BMI, triglycerides and cholesterol levels as well as diabetes status were variables that were adjusted for in this study. In summation, further research is required to elucidate the pathophysiologic role of FGF21 in HFpEF.

FGF21 in its native form has poor pharmacological properties and hence various analogues have been developed. Current clinical trials on FGF21 have focused predominantly on non-alcoholic steatohepatitis [43] and hypertriglyceridemia due to its potent lipid-lowering effects, despite the elevation of endogenous FGF21 levels in humans under these conditions [13,44]. FGF21 analogues have not yet met the endpoints of glycaemic control for type 2 diabetes, however, the combination of such drugs with antidiabetic medications has

produced potent antidiabetic effects. Despite these efforts, there have not yet been any clinical trials on the application of FGF21-based treatments to CVDs [45]. The findings from the present study may provide valuable insights regarding the future therapeutic potential of FGF21 for HF. Interestingly, the effects of sodium-glucose co-transporter 2 inhibitors, the first medication to improve cardiovascular outcomes in patients with HFpEF, are, in part, mediated by FGF21 [46–48]. Nevertheless, a recent study using Mendelian randomization did not support a causal role of FGF21 in HF [49]. However, it should be noted that this previous study was performed in the general populations of European ancestry and there was no data on the individual subtype of HF, whereas the association between baseline FGF21 and incident HFpEF observed in the present study was found only in participants with elevated FGF21, which may indicate the presence of FGF21 resistance. Additionally, Mendelian randomization is limited by the unknown functional status of the measured genes on other variables of interest. Further studies are needed to elucidate the potential pathophysiological role of FGF21 in HF.

This study benefits from utilizing data from the well-established MESA cohort, a large, multi-ethnic study with standardized protocols for measurement of sociodemographic, clinical characteristics and outcome events. Moreover, data on several important CVD risk biomarkers, namely CRP, fibrinogen, IL-6, and NT-proBNP, were available as covariates in the adjustment model. However, this study also has some limitations. FGF21 levels were measured at baseline only which precluded longitudinal analysis of the relationship between change in FGF21 levels and incident HF. Moreover, local tissue expression of FGF21 in the heart was not ascertained as in previous studies, only its circulating levels. We also could not exclude the possibility of residual confounding due to unmeasured confounding variables, as well as selection bias due to missing data in some covariates and HF subtype. Finally, the small number of incident HF cases also limited the further study of the two HF subtypes. Although the large sample size and the multi-ethnic study design of the MESA cohort as well as the use of different sensitivity analyses should enhance the generalisability of our findings, further studies in an independent cohort with similar participant characteristics are needed to validate the current findings.

In conclusion, the present study demonstrated a significant association of baseline FGF21 levels with incident HFpEF among participants with elevated baseline FGF21 levels. A larger independent longitudinal study analysing both HF subtypes will be required to validate the results of the present study given the potential limitations of residual confounding in the present study. Nevertheless, our findings may provide a good rationale for further preclinical and clinical studies to assess the potential therapeutic role of FGF21 analogues in the prevention and management of HFpEF.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

## Abbreviations:

| | |
|---|---|
| **BMI** | body mass index |
| **BNP** | brain natriuretic peptide |
| **BP** | blood pressure |
| **CAC** | coronary artery calcium |
| **CHD** | coronary heart disease |
| **CI** | confidence interval |
| **CRP** | C-reactive protein |
| **CVD** | cardiovascular disease |
| **eGFR** | estimated glomerular filtration rate |
| **FGF21** | fibroblast growth factor 21 |
| **FGFR** | fibroblast growth factor receptor |
| **GGT** | serum $\gamma$-glutamyl transferase |
| **HDL** | high density lipoprotein |
| **HF** | heart failure |
| **HFpEF** | heart failure with preserved ejection fraction |
| **HFrEF** | heart failure with reduced ejection fraction |
| **HOMA2-IR** | homeostasis model assessment of insulin resistance index |
| **HR** | hazards ratio |
| **IL-6** | interleukin 6 |

| LDL | low density lipoprotein |
| --- | --- |
| **LV** | left ventricular |
| **LVEF** | left ventricular ejection fraction |
| **MESA** | Multi-Ethnic Study of Atherosclerosis |
| **MRI** | magnetic resonance imaging |
| **NRI** | net reclassification improvement |
| **NT-proBNP** | N-terminal pro-brain natriuretic peptide |
| **ln** | natural logarithm |
| **SD** | standard deviation |

## References

[1]. Schwinger RH. Pathophysiology of heart failure. CardiovascDiagnTher 2021;11(1): 263–76. 10.21037/cdt-20-302.

[2]. Mosterd A, Cost B, Hoes A, De Bruijne M, Deckers J, Hofman A, et al. The prognosis of heart failure in the general population.The Rotterdam Study. Eur Heart J 2001; 22(15):1318–27. 10.1053/euhj.2000.2533. [PubMed: 11465964]

[3]. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2022;118(17):3272–87. 10.1093/cvr/cvac013.

[4]. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res 2015;106(1):19–31. 10.1093/cvr/cvu263. [PubMed: 25538153]

[5]. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013;4(1):2019. 10.1093/cvr/cvu263. [PubMed: 23771152]

[6]. Tucker W, Tucker B, Rye K-A, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev 2022;28(1):261–72. 10.1007/s10741-022-10268-0. [PubMed: 36028609]

[7]. Lakhani I, Gong M, Wong WT, Bazoukis G, Lampropoulos K, Wong SH, et al. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. Metabolism 2018;83:11–7. 10.1016/j.metabol.2018.01.017. [PubMed: 29410351]

[8]. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59 (11):2781–9. 10.2337/db10-0193. [PubMed: 20682689]

[9]. Geng L, Lam KS, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 2020;16(11):654–67. 10.1038/s41574-020-0386-0. [PubMed: 32764725]

[10]. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev 2023;28(1):261–72. 10.1007/s10741-022-10268-0. [PubMed: 36028609]

[11]. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156 (9):871–81. 10.1093/aje/kwf113. [PubMed: 12397006]

[12]. Salgado JV, Goes MA, Salgado Filho N. FGF21 and chronic kidney disease. Metabolism 2021;118:154738. 10.1016/j.metabol.2021.154738. [PubMed: 33617873]

[13]. Tucker B, Li H, Long X, Rye K-A, Ong KL. Fibroblast growth factor 21 in nonalcoholic fatty liver disease. Metabolism 2019;101:153994. 10.1016/j.metabol.2019.153994. [PubMed: 31672443]

[14]. Ong KL, Rye K-A, O'Connell R, Jenkins AJ, Brown C, Xu A, et al. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012;97(12): 4701–8. 10.1210/jc.2012-2267. [PubMed: 23144467]

[15]. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005;234(1):35–43. 10.1148/radiol.2341040439. [PubMed: 15618373]

[16]. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, et al. Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. Am J Roentgenol 2006;186(6_supplement_2):S357–65. 10.2214/AJR.04.1868. [PubMed: 16714609]

[17]. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008;52(25):2148–55. 10.1016/j.jacc.2008.09.014. [PubMed: 19095132]

[18]. Hui TH, McClelland RL, Allison MA, Rodriguez CJ, Kronmal RA, Heckbert SR, et al. The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2018; 269:86–91. 10.1016/j.atherosclerosis.2017.12.026. [PubMed: 29351855]

[19]. Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55(4): 622–7. 10.1053/j.ajkd.2010.02.337. [PubMed: 20338463]

[20]. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1487–95. 10.2337/diacare.27.6.1487. [PubMed: 15161807]

[21]. Veeranna V, Zalawadiya SK, Niraj A, Kumar A, Ference B, Afonso L. Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort. Int J Cardiol 2013;166(2):487–93. 10.1016/j.ijcard.2011.11.034. [PubMed: 22240756]

[22]. Choi E-Y, Bahrami H, Wu CO, Greenland P, Cushman M, Daniels LB, et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2012;5(6):727–34. 10.1161/CIRCHEARTFAILURE.112.968701. [PubMed: 23032197]

[23]. Bradley R, Fitzpatrick AL, Jenny NS, Lee D-H, Jacobs DR Jr. Associations between total serum GGT activity and metabolic risk: MESA. Biomark Med 2013;7(5): 709–21. 10.2217/bmm.13.71. [PubMed: 24044563]

[24]. Duprez DA, Gross MD, Kizer JR, Ix JH, Hundley WG, Jacobs DR Jr. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc 2018;7 (5):e007885. 10.1161/JAHA.117.007885. [PubMed: 29475876]

[25]. von Holstein-Rathlou S, Gillum MP. Fibroblast growth factor 21: an endocrine inhibitor of sugar and alcohol appetite. J Physiol 2019;597(14):3539–48. 10.1113/JP277117. [PubMed: 30921473]

[26]. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 2010;10(3):339–58. 10.1177/1536867X1001000303.

[27]. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30(1):11–21. 10.1002/sim.4085. [PubMed: 21204120]

[28]. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4(2):109–20. 10.1023/a:1009612305785. [PubMed: 9658770]

[29]. So WY, Cheng Q, Chen L, Evans-Molina C, Xu A, Lam KS, et al. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator–activated receptor γ signaling. Diabetes 2013;62(11):3751–9. 10.2337/db13-0645. [PubMed: 23897951]

[30]. Geng L, Liao B, Jin L, Huang Z, Triggle CR, Ding H, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep 2019;26(10):2738–2752. e4. 10.1016/j.celrep.2019.02.014. [PubMed: 30840894]

[31]. Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, et al. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PloS One 2014;9(2):e87102. 10.1371/journal.pone.0087102. [PubMed: 24498293]

[32]. Domouzoglou EM, Naka KK, Vlahos AP, Papafaklis MI, Michalis LK, Tsatsoulis A, et al. Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21. Am J Physiol Heart Circ Physiol 2015;309(6):H1029–38. 10.1152/ajpheart.00527.2015. [PubMed: 26232236]

[33]. Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-Pérez FJ, Mehta R, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PloS One 2012;7(5):e38022. 10.1371/journal.pone.0038022. [PubMed: 22701542]

[34]. Chen H, Lu N, Zheng M. A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. AmJTranslRes 2018;10(9):2958.

[35]. Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, et al. Serum fibroblast growth factor–21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 2010;59(11):1656–62. 10.1016/j.metabol.2010.03.018. [PubMed: 20423749]

[36]. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910. 10.1136/bmj.h910. [PubMed: 25740799]

[37]. Sommakia S, Almaw NH, Lee SH, Ramadurai DK, Taleb I, Kyriakopoulos CP, et al. FGF21 (Fibroblast Growth Factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail 2022;15:e008910. 10.1161/CIRCHEARTFAILURE.121.008910. [PubMed: 34865514]

[38]. Salah HM, Pandey A, Soloveva A, Abdelmalek MF, Diehl AM, Moylan CA, et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. JACC Basic Transl Sci 2021;6(11):918–32. 10.1016/j.jacbts.2021.07.010. [PubMed: 34869957]

[39]. Peters AE, Pandey A, Ayers C, Wegermann K, McGarrah RW, Grodin JL, et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Fail 2021;8(2):842–8. 10.1002/ehf2.13250. [PubMed: 33586354]

[40]. Auer J What does the liver tell us about the failing heart? Eur Heart J 2012;34(10): 711–4. 10.1093/eurheartj/ehs440. [PubMed: 23257947]

[41]. Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res 2021;117(2):423–34. 10.1093/cvr/cvaa217. [PubMed: 32666082]

[42]. Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC. Heart Fail 2018;6(8):701–9. 10.1016/j.jchf.2018.05.018. [PubMed: 30007554]

[43]. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 2018;392(10165): 2705–17. 10.1016/S0140-6736(18)31785-9. [PubMed: 30554783]

[44]. Lee Y, Lim S, Hong ES, Kim JH, Moon MK, Chun EJ, et al. Serum FGF 21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 2014;80:57–64. 10.1111/cen.12134. [PubMed: 23278761]

[45]. Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci 2023;19(1):66–88. 10.7150/ijbs.73936. [PubMed: 36594101]

[46]. Osataphan S, Macchi C, Singhal G, Chimene-Weiss J, Sales V, Kozuka C, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms. JCI Insight 2019;4(5):e123130. 10.1172/jci.insight.123130. [PubMed: 30843877]

[47]. Yang D, Zhang Y, Yan J, Liu M, An F. SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. FrontCardiovascMed 2022;9:942125. 10.3389/fcvm.2022.942125.

[48]. Cardoso R, Graffunder FP, Ternes CM, Fernandes A, Rocha AV, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine 2021;36:100933. 10.1016/j.eclinm.2021.100933. [PubMed: 34308311]

[49]. Larsson SC, Michaëlsson K, Mola-Caminal M, Höijer J, Mantzoros CS. Genome-wide association and mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH. Metabolism 2022;137:155329. 10.1016/j.metabol.2022.155329. [PubMed: 36208799]

**Fig. 1.**
Unadjusted Kaplan-Meier curves of HF development across FGF21 quartiles.

**Fig. 2.**
A plot of ln-transformed hazards ratio versus ln-transformed FGF21. The curve illustrates a cut-off value in ln-transformed FGF21 levels of approximately 5.48 (i.e. a FGF21 level of 239.0 pg/mL) for HF risk prediction following which the hazards ratio increases. The gray area indicates the 95 % CI.

**Table 1**

Baseline characteristics of the MESA participants included in the study.

| Characteristics | n | No HF ($n$ = 5066) | FH ($n$ = 342) | p | Adjusted p[b] |
|---|---|---|---|---|---|
| Age (years) | 5408 | 62.3 (10.2) | 68.3 (9.2) | <0.001 | <0.001 |
| Male (%) | 5408 | 47.0 (2380) | 56.1 (192) | 0.001 | <0.001 |
| Race/ethnicity (%) | 5408 | | | | |
| Non-Hispanic White | 2043 | 37.7 (1908) | 39.5 (135) | 0.073 | 0.009 |
| African American | 1600 | 29.4 (1488) | 32.7 (112) | | |
| Hispanic American | 1149 | 21.3 (1079) | 20.5 (70) | | |
| Chinese American | 616 | 11.7 (591) | 7.3 (25) | | |
| Education (%) | 5391 | | | | |
| <high school | 971 | 17.7 (896) | 22.0 (75) | 0.011 | 0.028 |
| High school | 2274 | 42.0 (2119) | 45.5 (155) | | |
| >high school | 2146 | 40.3 (2035) | 32.6 (111) | | |
| Family income (%) | 5177 | | | | |
| <$30,000 | 1940 | 36.8 (1788) | 46.9 (152) | <0.001 | 0.006 |
| $30,000–$75,000 | 2057 | 39.9 (1936) | 37.3 (121) | | |
| >$75,000 | 1180 | 23.3 (1129) | 15.7 (51) | | |
| Body mass index (kg/m^2) | 5408 | 28.2 (5.4) | 29.6 (5.9) | <0.001 | <0.001 |
| Physical activity[a] (MET-hour/week) | 5393 | 67.3 (32.8–125.0) | 58.3 (25.3–108.9) | 0.042 | 0.133 |
| Smoking (%) | 5391 | | | | |
| Never | 2704 | 50.6 (2554) | 44.0 (150) | 0.019 | 0.053 |
| Former | 2007 | 36.8 (1856) | 44.3 (151) | | |
| Current | 680 | 12.7 (640) | 11.7 (40) | | |
| Pack years of smoking | 5333 | 11.0 (20.1) | 15.5 (26.3) | 0.002 | 0.001 |
| Alcohol use (%) | 5367 | | | | |
| Never | 1090 | 20.4 (1025) | 19.1 (65) | <0.001 | <0.001 |
| Former | 1283 | 23.2 (1165) | 34.6 (118) | | |
| Current | 2994 | 56.4 (2836) | 46.3 (158) | | |
| Lipid-lowering medications (%) | 5397 | 16.7 (844) | 21.7 (74) | 0.017 | 0.681 |
| LDL cholesterol (mg/dL) | 5336 | 117.8 (31.5) | 114.0 (32.4) | 0.032 | 0.101 |
| HDL cholesterol (mg/dL) | 5398 | 51.2 (15.0) | 49.5 (14.0) | 0.049 | 0.024 |
| Triglycerides[a] (mg/dL) | 5401 | 109 (77–160) | 117 (76–161) | 0.222 | 0.010 |
| eGFR (mL/min/1.73 m$^2$) | 5399 | 78.0 (15.9) | 71.8 (17.7) | <0.001 | 0.042 |
| Systolic BP (mmHg) | 5407 | 126 (21) | 137 (23) | <0.001 | <0.001 |
| Diastolic BP (mmHg) | 5407 | 72 (10) | 73 (12) | 0.031 | 0.012 |
| Anti-hypertensive medications (%) | 5406 | 36.0 (1821) | 59.1 (202) | <0.001 | <0.001 |
| Diabetes (%) | 5399 | 11.7 (592) | 27.5 (94) | <0.001 | <0.001 |
| HOMA2-IR[a] | 5385 | 0.91 (0.66–1.36) | 1.07 (0.73–1.50) | <0.001 | <0.001 |
| IL-6[a] (pg/mL) | 5269 | 1.2 (0.7–1.9) | 1.5 (1.0–2.4) | <0.001 | <0.001 |
| CRP[a] (mg/L) | 5378 | 1.9 (0.8–4.2) | 2.4 (1.0–5.0) | 0.004 | <0.001 |

| Characteristics | n | No HF ($n$ = 5066) | FH ($n$ = 342) | p | Adjusted p[b] |
|---|---|---|---|---|---|
| Fibrinogen (mg/dL) | 5380 | 346 (73) | 365 (77) | <0.001 | <0.001 |
| NT-proBNP[a] (pg/mL) | 5402 | 51.2 (23.2–102.5) | 109.2 (52.7–232.9) | <0.001 | <0.001 |
| FGF21[a] (pg/mL) | 5408 | 145.0 (81.1–241.3) | 170.3 (97.1–313.0) | <0.001 | 0.001 |
| LV end diastolic mass (g) | 3912 | 144.1 (38.4) | 172.3 (51.0) | <0.001 | <0.001 |
| LV end diastolic volume (mL) | 3912 | 125.3 (30.6) | 140.0 (39.5) | <0.001 | <0.001 |
| LV end systolic volume (mL) | 3912 | 39.3 (15.9) | 50.7 (29.3) | <0.001 | <0.001 |
| LV stroke volume (mL) | 3912 | 85.9 (19.6) | 89.2 (20.0) | 0.016 | <0.001 |
| LV ejection fraction (%) | 3912 | 69.2 (7.2) | 65.5 (10.5) | <0.001 | <0.001 |

Data are expressed as mean (SD), percent (n), or median (interquartile range). Data was compared by chi square test for categorical variables and independent t-test for continuous variables.

[a] ln-transformed before analysis.

[b] Adjusted for age, sex, and race/ethnicity in Cox regression analysis.

**Table 2**

Correlates of ln-transformed plasma FGF21 levels in multivariable linear regression analysis.

| Characteristics | Unadjusted | | Model 1 | | Model 2 | |
|---|---|---|---|---|---|---|
| | % change (95 % CI) | p | % change (95 % CI) | p | % change (95 % CI) | p |
| Age (years) | 22.2 (17.9, 26.6) | <0.001 | 22.4 (18.1, 26.8) | <0.001 | 11.4 (6.1, 17.0) | <0.001 |
| Male (%) | −10.5 (−16.7, −3.8) | 0.003 | −10.6 (−16.8, −4.0) | 0.002 | −7.2 (−14.9, 1.3) | 0.096 |
| Race/ethnicity (%) | | | | | | |
| Non-Hispanic White | reference | – | reference | – | reference | – |
| African American | −14.7 (−21.9, −6.8) | <0.001 | −14.1 (−21.3, −6.2) | <0.001 | −14.5 (−22.6, −5.5) | 0.002 |
| Hispanic American | 11.8 (1.4, 23.2) | 0.025 | 13.9 (3.4, 25.4) | 0.008 | −5.8 (−15.9, 5.5) | 0.298 |
| Chinese American | −17.3 (−26.7, −6.6) | 0.002 | −17.9 (−27.2, −7.4) | 0.001 | −14.0 (−25.0, −1.4) | 0.030 |
| Education (%) | | | | | | |
| <high school | reference | – | reference | – | reference | – |
| High school | −4.2 (−13.4, 6.1) | 0.412 | 3.5 (−6.9, 15.2) | 0.521 | 9.7 (−1.9, 22.7) | 0.104 |
| >high school | −26.6 (−33.8, −18.8) | <0.001 | −16.0 (−25.0, −5.9) | 0.003 | 2.8 (−9.3, 16.5) | 0.665 |
| Family income (%) | | | | | | |
| <$30,000 | reference | – | reference | – | reference | – |
| $30,000–$75,000 | −11.7 (−18.8, −3.9) | 0.004 | −4.2 (−12.3, 4.7) | 0.345 | −2.0 (−10.6, 7.5) | 0.672 |
| >$75,000 | −31.3 (−37.3, −24.2) | <0.001 | −23.5 (−31.4, −14.7) | <0.001 | −9.0 (−19.1, 2.3) | 0.114 |
| Body mass index (kg/m$^2$) | 20.5 (16.3, 24.9) | <0.001 | 24.9 (20.3, 29.7) | <0.001 | 3.8 (−1.2, 9.0) | 0.137 |
| Physical activity[a] (MET-hour/week) | −11.4 (−14.6, −8.2) | <0.001 | −7.9 (−11.3, −4.4) | <0.001 | −3.9 (−7.5, −0.1) | 0.045 |
| Smoking (%) | | | | | | |
| Never | reference | – | reference | – | reference | – |
| Former | 8.2 (0.0, 17.0) | 0.049 | 7.6 (−0.6, 16.5) | 0.070 | 5.6 (−3.9, 16.0) | 0.259 |
| Current | 21.1 (8.1, 35.7) | <0.001 | 35.9 (21.2, 52.4) | <0.001 | 19.5 (4.4, 36.8) | 0.010 |
| Pack years of smoking | 10.4 (6.4, 14.4) | <0.001 | 10.1 (6.2, 14.3) | <0.001 | 3.1 (−1.3, 7.8) | 0.169 |
| Alcohol use (%) | | | | | | |
| Never | reference | – | reference | – | reference | – |
| Former | −14.3 (−23.2, −4.4) | 0.006 | −12.4 (−21.8, −1.7) | 0.024 | −18.2 (−27.4, −7.9) | <0.001 |
| Current | −13.4 (−21.1, −4.9) | 0.003 | −9.6 (−18.4, 0.2) | 0.053 | −7.8 (−17.3, 2.7) | 0.140 |
| Lipid-lowering medications (%) | 26.1 (14.6, 38.8) | <0.001 | 16.8 (6.2, 28.6) | 0.001 | 9.3 (−1.3, 21.0) | 0.089 |

| Characteristics | Unadjusted | | Model 1 | | Model 2 | |
|---|---|---|---|---|---|---|
| | % change (95 % CI) | p | % change (95 % CI) | p | % change (95 % CI) | p |
| LDL cholesterol (mg/dL) | −3.4 (−6.9, 0.1) | 0.060 | −3.0 (−6.4, 0.5) | 0.094 | −3.1 (−6.7, 0.7) | 0.109 |
| HDL cholesterol (mg/dL) | −14.4 (−17.4, −11.3) | <0.001 | −19.7 (−22.7, −16.6) | <0.001 | −0.5 (−5.1, 4.4) | 0.847 |
| Triglycerides[a] (mg/dL) | 40.7 (35.9, 45.7) | <0.001 | 42.2 (37.2, 47.3) | <0.001 | 30.4 (24.5, 36.6) | <0.001 |
| eGFR (mL/min/1.73 m$^2$) | −15.4 (−18.4, −12.3) | <0.001 | −7.9 (−11.7, −4.0) | <0.001 | −6.6 (−10.6, −2.5) | 0.002 |
| Systolic BP (mmHg) | 19.6 (15.4, 24.0) | <0.001 | 14.5 (10.2, 19.0) | <0.001 | 4.4 (0.3, 8.8) | 0.037 |
| Diastolic BP (mmHg) | 4.1 (0.4, 8.0) | 0.028 | 10.1 (6.0, 14.4) | <0.001 | – | – |
| Anti-hypertensive medications (%) | 37.7 (27.9, 48.3) | <0.001 | 28.9 (19.3, 39.2) | <0.001 | 6.9 (−1.7, 16.3) | 0.120 |
| Diabetes (%) | 47.2 (32.2, 64.0) | <0.001 | 42.4 (27.8, 58.7) | <0.001 | 10.6 (−1.7, 24.5) | 0.094 |
| HOMA2-IR[a] | 30.5 (25.9, 35.2) | <0.001 | 31.7 (27.1, 36.4) | <0.001 | 9.9 (4.9, 15.2) | <0.001 |
| IL-6[a] (pg/mL) | 31.2 (26.6, 35.9) | <0.001 | 27.4 (22.7, 32.2) | <0.001 | 17.2 (11.9, 22.8) | <0.001 |
| CRP[a] (mg/L) | 24.4 (20.0, 28.9) | <0.001 | 23.7 (19.2, 28.4) | <0.001 | 6.4 (1.3, 11.7) | 0.013 |
| Fibrinogen (mg/dL) | 9.5 (5.7, 13.6) | <0.001 | 5.3 (1.4, 9.3) | 0.007 | −9.7 (−13.7, −5.5) | <0.001 |
| NT pro-BNP[a] (pg/mL) | 12.2 (8.2, 16.3) | <0.001 | −0.6 (−4.7, 3.8) | 0.796 | – | – |

Regression coefficient B (95 % confidence interval) were expressed as percentage change in FGF21 levels per one SD unit increase in continuous variables. The percentage change was estimated by the exponentiation of coefficients from linear regression analysis, in which ln-transformed FGF21 was the dependent variable. Model 1 was adjusted for age, sex, and race/ethnicity. Variables with $p < 0.2$ in Model 1 were entered into the multivariable regression analysis for model 2. Diastolic BP was not entered into the model due to multi-collinearity with systolic BP.

[a]Data were ln-transformed before analysis.

Association of baseline ln-transformed plasma FGF21 levels with incident HF.

| Heart failure | No. of events, % (n) | Model 1 | | Model 2 | | Model 3 | |
|---|---|---|---|---|---|---|---|
| | | HR (95 % CI) | p | HR (95 % CI) | p | HR (95 % CI) | p |
| **All HF** | | | | | | | |
| All | 6.3 (342) | 1.23 (1.07, 1.42) | 0.004 | 1.15 (0.99, 1.33) | 0.075 | 1.12 (0.96, 1.31) | 0.138 |
| FGF21 < 239.0 pg/mL | 5.6 (223) | 1.08 (0.91, 1.28) | 0.377 | 1.00 (0.84, 1.18) | 0.967 | 0.99 (0.83, 1.18) | 0.916 |
| FGF21 239.0 pg/mL | 8.5 (119) | 1.56 (1.10, 2.20) | 0.012 | 1.52 (1.03, 2.25) | 0.035 | 1.84 (1.21, 2.80) | 0.004 |
| p for heterogeneity | | | 0.071 | | 0.050 | | 0.004 |
| **HFpEF** | | | | | | | |
| All | 48.8 (167) | 1.30 (1.05, 1.60) | 0.018 | 1.20 (0.96, 1.51) | 0.112 | 1.15 (0.91, 1.45) | 0.241 |
| FGF21 < 239.0 pg/mL | 2.5 (101) | 1.01 (0.80, 1.27) | 0.943 | 0.92 (0.73, 1.16) | 0.488 | 0.90 (0.71, 1.14) | 0.386 |
| FGF21 239.0 pg/mL | 4.7 (66) | 1.81 (1.21, 2.72) | 0.004 | 2.02 (1.24, 3.30) | 0.005 | 2.57 (1.51, 4.37) | <0.001 |
| p for heterogeneity | | | 0.011 | | 0.002 | | <0.001 |
| **HFrEF** | | | | | | | |
| All | 40.9 (140) | 1.20 (0.98, 1.48) | 0.083 | 1.14 (0.92, 1.42) | 0.239 | 1.12 (0.89, 1.40) | 0.344 |
| FGF21 < 239.0 pg/mL | 2.4 (97) | 1.18 (0.89, 1.56) | 0.242 | 1.12 (0.84, 1.49) | 0.454 | 1.10 (0.82, 1.46) | 0.537 |
| FGF21 239.0 pg/mL | 3.1 (43) | 1.06 (0.50, 2.26) | 0.876 | 1.01 (0.46, 2.24) | 0.984 | 1.13 (0.49, 2.61) | 0.776 |
| p for heterogeneity | | | 0.787 | | 0.706 | | 0.923 |

Hazards ratio (HR) was expressed per one SD increase (1.357) in ln-transformed FGF21 levels. Data is expressed as percent (n) for HF events.

Model 1: Adjusted for age, sex, race/ethnicity, education, and family income.

Model 2: Further adjusted for BMI, physical activity, smoking, pack-year of smoking, alcohol use, LDL cholesterol, HDL cholesterol, triglycerides, lipid-lowering medications, eGFR, systolic BP, anti-hypertensive medication, diabetes, and HOMA2-IR.

Model 3: Further adjusted for CRP, IL- 6, fibrinogen, and ln-transformed NT-proBNP.

**Table 4**

Assessment of incremental value of biomarkers in risk prediction for incident HFpEF.

| Prediction Model | NRI (>0), % (95 % CI) | Event NRI (%)[a] | Non-event NRI (%)[b] | C-statistics | p | May and Hosmer test | |
|---|---|---|---|---|---|---|---|
| | | | | | | Chi-square | p |
| Base Model | – | – | – | 0.804 | – | 0.2 | 0.978 |
| + FGF21 | 14.4 (−4.5, 47.7) | −35.5 | 49.9 | 0.810 | 0.003 | 0.7 | 0.870 |
| + NT-proBNP | 53.3 (30.3, 80.2)* | 33.5 | 19.9 | 0.824 | <0.001 | 2.0 | 0.569 |
| + CRP | 15.1 (−16.5, 30.3) | −19.3 | 34.4 | 0.804 | 0.645 | 0.2 | 0.978 |
| + IL-6 | 2.3 (−17.4, 39.9) | −29.0 | 31.3 | 0.806 | 0.092 | 1.3 | 0.739 |
| + fibrinogen | 5.6 (−14.1, 32.0) | −4.2 | 9.8 | 0.805 | 0.196 | 0.2 | 0.984 |
| Base Model + CRP + IL–6 + fibrinogen + NT-proBNP | – | – | – | 0.824 | – | 2.7 | 0.442 |
| + FGF21 | 19.6 (1.5, 51.2)* | −35.4 | 55.0 | 0.829 | <0.001 | 0.4 | 0.932 |
| Base Model + NT-proBNP | – | – | – | 0.824 | – | 2.0 | 0.569 |
| + FGF21 | 17.7 (4.7, 51.6)* | −37.9 | 55.6 | 0.830 | 0.001 | 0.5 | 0.919 |

FGF21 and NT-proBNP were ln-transformed in the analysis. Estimates were calculated for the 10-year risk.

Base model includes age, sex, race/ethnicity, education, family income, BMI, physical activity, smoking, pack-year of smoking, alcohol use, LDL cholesterol, triglycerides, lipid-lowering medications, eGFR, systolic BP, anti-hypertensive medication, diabetes, and HOMA2-IR. FGF21 and NT-proBNP were ln-transformed prior to analysis. For ln-transformed FGF21, a piecewise Cox regression model was fitted with two slopes and a change point at a FGF21 level of 239.0 pg/mL. The category-less NRI (>0) measures the improvement associated with correct upward or downward change in predicted risks and was calculated as the proportion of participant with events with correct upward or downward change minus incorrect upward or downward change plus the corresponding proportion among participants without events. A value >0 indicates improved risk prediction and discrimination associated with the addition of a biomarker as compared to the base model.

The C-statistic measures discrimination and estimates the probability that, of two randomly chosen participants, the participant with the higher predicted risk will remain event-free longer than the participant with the lower predicted risk. A C-statistic near 0.5 indicates the predicted score has an equally likely and unlikely chance in determining which participant will remain event-free longer. A value above 0.5 indicates an improved ability of the model to correctly predict the outcome, with a value of 1 indicating a perfect prediction of the event. The May and Hosmer test assesses the overall goodness of fit of a model based on grouping the subjects by their estimated risk score and comparing the number of observed and model-based estimated number of expected events within each group. A significant test result indicates differences between observed and expected numbers of events and hence lack of fit.

*
 $p < 0.05$.

[a] Percentage correctly reclassified among participants who had events.

[b] Percentage correctly reclassified among participants who did not have events.